Compounds, compositions and methods for treating ocular conditions
The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.
1. An ophthalmic composition comprising: an ophthalmically acceptable carrier and a compound in an amount effective to treat a viral infection, wherein said compound is
or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The composition of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
4. The composition of claim 1 , wherein the composition comprises a topically acceptable carrier.
5. The composition of claim 1 , wherein the ophthalmic composition is in the form selected from the group consisting of an aqueous solution, a non-aqueous solution, a suspension, a solution/suspension, a gel, a cream, an ointment, and an emulsion.
6. The composition of claim 1 , wherein the composition further comprises at least one excipient selected from the group consisting of stabilizer, a penetrating enhancer, a pH adjusting agent, an antimicrobial preservative, a lubricant, a viscosifier, and a wetting agent.
7. The composition of claim 1 , further comprises purified water, carbomer, trolamine, propylparaben, methylparaben, propylene glycol, and glycerin.
8. The composition of claim 1 , wherein the amount of the compound is in the range of about 0.001% to 30% by weight.
9. The composition of claim 8 , wherein the amount of the compound is about 5% by weight.
10. A method of treating a viral infection of the eye comprising administering an ophthalmic composition to a subject, wherein the composition comprises an ophthalmically acceptable carrier and
or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
12. The method of claim 10 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The method of claim 10 , wherein said viral infection is selected from the group consisting of influenza, herpes simplex virus (HSV), human herpes virus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), orthopox virus, variola major and minor, vaccinia, cowpox, camelpox, monkeypox, papilloma virus, adenovirus, polyoma virus including JC virus, BK virus, SV40 and a combination thereof.
14. The method of claim 13 , wherein said viral infection is selected from the groups consisting of cytomegalovirus, varicella zoster virus, adenovirus, herpes simplex virus and Epstein-Barr virus.
15. The method of claim 10 , wherein the composition is topically administered to the eye.
16. The method of claim 15 , wherein the composition is topically administered to the cornea and/or conjunctiva of the subject.
17. The method of claim 10 , wherein the composition is intraocularly administered.
18. The method of claim 17 , wherein the composition is administered by intraocular injection.
19. The method of claim 18 , wherein the composition is administered by retrobulbar, intravitreal, intraretinal or subconjunctival injection.
20. The method of claim 10 , wherein the viral infection is due to a double stranded DNA (dsDNA) virus.